¼¼°èÀÇ Æó¾Ï ¾×ü»ý°Ë ½ÃÀå : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)
Lung Cancer Liquid Biopsy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
ÁÖ¿ä Á¶»ç °á°ú
Æó¾Ï ¾×ü»ý°Ë ½ÃÀå ±Ô¸ð : 8¾ï 2,470¸¸ ´Þ·¯(2025³â)
¿¹»ó ½ÃÀå ±Ô¸ð : 19¾ï 50¸¸ ´Þ·¯(2032³â)
¼¼°è ½ÃÀå ¼ºÀå·ü: 12.7%(2025-2032³â CAGR)
Æó¾Ï ¾×ü»ý°Ë ½ÃÀå - º¸°í¼ ¹üÀ§
Æó¾Ï ¾×ü»ý°Ë ½ÃÀåÀº Æó¾Ï ȯÀÚÀÇ Á¾¾ç ¹ÙÀÌ¿À¸¶Ä¿¸¦ °ËÃâÇϱâ À§ÇØ Ç÷¾× ¹× ±âŸ ü¾×À» »ç¿ëÇÏ´Â ºñħ½ÀÀû Áø´Ü ¹æ¹ý¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ »ý°ËÀº ºü¸¥ ½Ã°£, ȯÀÚÀÇ ºÒÆí°¨ °¨¼Ò, Á¾¾ç ÁøÇà ¹× Ä¡·á È¿°úÀÇ ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ¸·Î ¾Ï Áø´Ü ¹× °ü¸®¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î Æó¾Ï ¹ßº´·üÀÌ Áõ°¡Çϰí Á¤¹ÐÀÇ·áÀÇ µµÀÔÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾×ü»ý°ËÀº Á¾¾ç Áø´ÜÀÇ °·ÂÇÑ µµ±¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â ¼Ò¼¼Æ÷Æó¾Ï(SCLC)°ú ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC)ÀÇ Á¶±â ¹ß°ß, À¯ÀüÀÚ ÇÁ·ÎÆÄÀϸµ, Ä¡·á ¹æÄ§ °áÁ¤À» À§ÇØ ¼³°èµÈ ±â±â, ½Ã¾à, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼Ö·ç¼Ç µî ´Ù¾çÇÑ Á¦Ç° ¹× ¼ºñ½º°¡ Æ÷ÇԵ˴ϴÙ.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
¼¼°è Æó¾Ï ¾×ü»ý°Ë ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è Æó¾Ï À¯º´·ü Áõ°¡¿Í ÃÖ¼Òħ½ÀÀû Áø´Ü¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ Å©°Ô ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ºÐÀÚÁø´Ü, ƯÈ÷ Â÷¼¼´ë ¿°±â¼¿ ºÐ¼®(NGS) ¹× PCR ±â¹Ý ±â¼úÀÇ ¹ßÀüÀº ¾×ü»ý°Ë °Ë»ç¸¦ º¸´Ù Á¤È®ÇÏ°í ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ ÀÇ·á Á¦°ø¾÷ü¿Í Á¾¾ç Àü¹®ÀǵéÀÌ ½Ç½Ã°£ Á¾¾ç ÇÁ·ÎÆÄÀϸµ ¹× ¸ð´ÏÅ͸µ¿¡ ¾×ü»ý°ËÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ Àû±ØÀûÀÎ ½ÂÀΰú ƯÈ÷ ¼±Áø±¹¿¡¼ µÎµå·¯Áø ÀÇ·áºñ Áõ°¡´Â ½ÃÀå È®´ë¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¶±â ¾Ï Áø´Ü¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡¿Í ±âÁ¸ Á¶Á÷ »ý°ËÀÇ ÇѰ踦 ±Øº¹ÇÒ ¼ö ÀÖ´Â ¾×ü»ý°ËÀÇ ÀáÀç·Âµµ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
À¯¸ÁÇÑ ¼ºÀå ±Ëµµ¿¡µµ ºÒ±¸ÇÏ°í Æó¾Ï ¾×ü»ý°Ë ½ÃÀåÀº ¿©·¯ °¡Áö ÁÖ¿ä °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÷´Ü ¾×ü»ý°Ë ±â¼úÀÇ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ƯÈ÷ ÁßÀú¼Òµæ ±¹°¡¿¡¼ äÅÃÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ÀϺΠºÐ¼®¹ýÀÇ ¹Î°¨µµ¿Í ƯÀ̵µ´Â ƯÈ÷ Á¶±â ¾Ï ¹ß°ß¿¡¼ À§¾ç¼º ¶Ç´Â À§À½¼ºÀ» À¯¹ßÇÒ ¼ö ÀÖ¾î ¿©ÀüÈ÷ ¿ì·ÁµÇ´Â ¹®Á¦ÀÔ´Ï´Ù. ÀϺΠÁö¿ª¿¡¼´Â ȯÀÚ¿Í ÀÇ·áÁøÀÇ ³·Àº ÀÎÁöµµ°¡ ½ÃÀå ħÅõ¿¡ °É¸²µ¹ÀÌ µÇ±âµµ ÇÕ´Ï´Ù. ¶ÇÇÑ, ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í »óȯ Àå¾Ö¹°Àº Á¦Ç° Ãâ½Ã¸¦ Áö¿¬½ÃŰ°Å³ª Á¢±Ù¼ºÀ» Á¦ÇÑÇÏ¿© Àüü ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ
Æó¾Ï ¾×ü»ý°Ë ½ÃÀåÀº Áø´Ü Á¤È®µµ¸¦ ³ôÀÏ ¼ö ÀÖ´Â ¼¼Æ÷¿Ü¼ÒÆ÷ ¹× ¼øÈ¯ Á¾¾ç¼¼Æ÷¿Í °°Àº »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸ÀÇ È®´ë·Î ÀÎÇØ Å« ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ´ÙºÐ¼® ¾×ü»ý°Ë ÆÐ³ÎÀÇ °³¹ß°ú ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º¿¡ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕÀº Áø´ÜÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â ±æÀ» Á¦°øÇÕ´Ï´Ù. ƯÈ÷ ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× ¶óƾ¾Æ¸Þ¸®Ä« µî ½ÅÈï °æÁ¦±¹Àº ¾Ï ¹ßº´·ü Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶óÀÇ È®ÀåÀ¸·Î ÀÎÇØ ¾ÆÁ÷ °³¹ßµÇÁö ¾ÊÀº ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç¥ÀûÄ¡·áÀÇ µ¿¹ÝÁø´ÜÀ» À§ÇÑ Áø´Ü±â¾÷°ú Á¦¾à±â¾÷°úÀÇ Á¦ÈÞ´Â »õ·Î¿î ¼ºÀåÀÇ ±æÀ» ¿¾îÁÖ°í ÀÖ½À´Ï´Ù. »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿ Á¶ÇÕÀÇ °ËÁõÀ» À§ÇÑ ¿¬±¸°³¹ß°ú ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ´Â ±â¼ú Çõ½Å°ú ½ÃÀå¿¡¼ÀÇ °æÀï·ÂÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
ÀÌ º¸°í¼´Â ¼¼°è Æó¾Ï ¾×ü»ý°Ë ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ¼ºÀå ÃËÁø¿äÀÎ, µ¿Çâ, ±âȸ, °úÁ¦ µî ½ÃÀå ¿ªÇп¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¼ºÀå ¾ïÁ¦¿äÀÎ
±âȸ
ÁÖ¿ä µ¿Çâ
°Å½Ã°æÁ¦ ¿äÀÎ
¼¼°èÀÇ ºÎ¹® Àü¸Á
¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
COVID-19ÀÇ ¿µÇ⠺м®
¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®
Á¦Ç° äÅà ºÐ¼®
Áúº´ ¿ªÇÐ
±ÔÁ¦ »óȲ
°ø±Þ¾÷ü ¸®½ºÆ®
PorterÀÇ Five Forces ºÐ¼®
PESTLE ºÐ¼®
ÇÁ·Î¸ð¼Ç Àü·« : ÁÖ¿ä ±â¾÷º°
Á¦4Àå ¼¼°èÀÇÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð¿Í Àü³â´ëºñ ¼ºÀå
Àý´ëÀû ¸ÅÃâ ±âȸ
½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø
½ÃÀå ±Ô¸ð ºÐ¼®(2019³â-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø(2025³â-2032³â)
¼¼°èÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á : Á¦Ç°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð ºÐ¼® : Á¦Ç°º°(2019³â-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Á¦Ç°º°(2025³â-2032³â)
±â±¸
ŰƮ ¹× ½Ã¾à
¼ÒÇÁÆ®¿þ¾î ¹× ¼ºñ½º
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Á¦Ç°
¼¼°èÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á : ±â¼ú
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð : ±â¼úº°(2019³â-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±â¼úº°(2025³â-2032³â)
¸ÖƼ À¯ÀüÀÚ º´·Ä ÇØ¼®(NGS)
´ÜÀÏ À¯ÀüÀÚ ºÐ¼®(PCR ¸¶ÀÌÅ©·Î¾î·¹ÀÌ)
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ±â¼ú
¼¼°èÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á : ¹ÙÀÌ¿À¸¶Ä¿
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð : ¹ÙÀÌ¿À¸¶Ä¿º°(2019³â-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ¹ÙÀÌ¿À¸¶Ä¿º°(2025³â-2032³â)
cfDNA
ctDNA
¼¼Æ÷¿Ü¼ÒÆ÷(EV)
¼øÈ¯Á¾¾ç¼¼Æ÷(CTC)
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ¹ÙÀÌ¿À¸¶Ä¿
¼¼°èÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á : ÀûÀÀÁõ
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð : ÀûÀÀÁõº°(2019³â-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÀûÀÀÁõº°(2025³â-2032³â)
¼Ò¼¼Æ÷ Æó¾Ï(SCLC)
ºñ¼Ò¼¼Æ÷ Æó¾Ï(NSCLC)
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÀûÀÀÁõ
¼¼°èÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á : »ùÇÃ
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð, »ùÇú°(2019³â-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : »ùÇú°(2025³â-2032³â)
Ç÷¾×
³úô¼ö¾×(CSF)
Ç÷Àå
Ç÷û
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : »ùÇÃ
¼¼°èÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á : ÃÖÁ¾»ç¿ëÀÚ
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð : ÃÖÁ¾»ç¿ëÀÚº°(2019³â-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2025³â-2032³â)
º´¿ø
ÂüÁ¶ ½ÇÇè½Ç
Çмú¿¬±¸±â°ü
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚ
Á¦5Àå ¼¼°èÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á : Áö¿ª
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð ºÐ¼® : Áö¿ªº°(2019³â-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°(2025³â-2032³â)
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ª
Á¦6Àå ºÏ¹ÌÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á
Á¦7Àå À¯·´ÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á
Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á
Á¦9Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á
Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á
Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Æó¾Ï ¾×ü»ý°Ë Àü¸Á
Á¦12Àå °æÀï ±¸µµ
½ÃÀå Á¡À¯À² ºÐ¼®(2025³â)
½ÃÀå ±¸Á¶
°æÀï °µµ ¸Ê : ½ÃÀ庰
°æÀï ´ë½Ãº¸µå
±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù ¹ßÀü)
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Oncocyte Corporation
NeoGenomics Laboratories
Lepu Medical Technology(Beijing) Co., Ltd
QIAGEN
Thermo Fisher Scientific Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Sysmex Corporation
BioView
Guardant Health, Inc
SOPHiA GENETICS
BioMark Diagnostics
DELFI Diagnostics, Inc.
Freenome Holdings, Inc.
Foresight Diagnostics, Inc.
Foundation Medicine, Inc.
Pillar Biosciences, Inc.
Caris Life Sciences
Á¦13Àå ºÎ·Ï
LSH
Persistence Market Research has recently released a comprehensive report on the global Lung Cancer Liquid Biopsy Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.
Key Insights:
Lung Cancer Liquid Biopsy Market Size (2025E): US$ 824.7 Mn
Projected Market Value (2032F): US$ 1,900.5 Mn
Global Market Growth Rate (CAGR 2025 to 2032): 12.7%
Lung Cancer Liquid Biopsy Market - Report Scope:
The lung cancer liquid biopsy market focuses on non-invasive diagnostic methods that utilize blood and other body fluids to detect tumor biomarkers in lung cancer patients. These biopsies are revolutionizing cancer diagnostics and management by offering quicker turnaround times, reduced patient discomfort, and real-time monitoring of tumor progression or therapy response. With rising lung cancer incidence globally and increasing adoption of precision medicine, liquid biopsy is emerging as a powerful tool in oncology diagnostics. This market includes a wide range of products and services, including instruments, reagents, and bioinformatics solutions designed for early detection, genetic profiling, and therapeutic decision-making in both Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC).
Market Growth Drivers:
The growth of the global lung cancer liquid biopsy market is being significantly driven by the rising global prevalence of lung cancer, coupled with a growing demand for minimally invasive diagnostic procedures. Technological advancements in molecular diagnostics, particularly in next-generation sequencing (NGS) and PCR-based techniques, are making liquid biopsy tests more accurate and accessible. Additionally, increasing focus on personalized medicine is pushing healthcare providers and oncologists to adopt liquid biopsies for real-time tumor profiling and monitoring. Supportive regulatory approvals and increasing healthcare spending, especially in developed nations, are further contributing to market expansion. The growing preference for early and precise cancer detection methods and the potential of liquid biopsies to overcome limitations of traditional tissue biopsies are also propelling market demand.
Market Restraints:
Despite the promising growth trajectory, the lung cancer liquid biopsy market faces several key challenges. High costs associated with advanced liquid biopsy technologies can restrict adoption, particularly in low- and middle-income countries. The sensitivity and specificity of some assays, especially in early-stage cancer detection, remain areas of concern, potentially leading to false positives or negatives. Limited awareness among patients and healthcare providers in certain regions further impedes market penetration. Additionally, stringent regulatory frameworks and reimbursement hurdles can delay product launches and limit accessibility, affecting overall market growth.
Market Opportunities:
The lung cancer liquid biopsy market presents considerable opportunities fueled by the expansion of research into new biomarkers, including extracellular vesicles and circulating tumor cells, which can enhance diagnostic accuracy. The ongoing development of multi-analyte liquid biopsy panels and integration of AI and machine learning in bioinformatics offer pathways to improved diagnostic precision and efficiency. Emerging economies, especially across Asia-Pacific and Latin America, represent untapped potential with growing cancer burden and expanding healthcare infrastructure. Furthermore, collaborations between diagnostic companies and pharmaceutical firms for companion diagnostics in targeted therapies are opening new growth avenues. Continued investment in R&D and clinical trials aimed at validating new biomarker combinations will likely drive innovation and market competitiveness.
Key Questions Answered in the Report:
What are the primary factors driving the global lung cancer liquid biopsy market's growth?
Which regions and market segments are experiencing the highest demand for lung cancer liquid biopsy diagnostics?
How are advancements in genomics and personalized oncology influencing market dynamics?
Who are the key players in the lung cancer liquid biopsy market, and what strategies are they adopting to stay competitive?
What are the emerging trends and future projections for the global lung cancer liquid biopsy market?
Competitive Intelligence and Business Strategy:
Leading players in the global lung cancer liquid biopsy market, such as Bio-Rad Laboratories, Agilent Technologies, Thermo Fisher Scientific, Illumina, and F. Hoffmann-La Roche, are focusing on developing high-sensitivity diagnostic platforms and expanding their liquid biopsy portfolios. These companies are increasingly investing in strategic collaborations with research institutions and biotech firms to enhance their R&D capabilities. Mergers, acquisitions, and licensing agreements are common strategies aimed at boosting technological integration and expanding global reach. Key players are also emphasizing regulatory approvals and global certifications to gain market trust and improve reimbursement prospects. Efforts to combine multiple biomarkers into single-panel tests and the integration of cloud-based platforms for data interpretation are setting new standards in the field.
Companies Covered in This Report:
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Oncocyte Corporation
NeoGenomics Laboratories
Lepu Medical Technology (Beijing) Co., Ltd
QIAGEN
Thermo Fisher Scientific Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Sysmex Corporation
BioView
Market Segmentation
By Product:
Instruments
Kits and Reagents
Software and Services
By Technology:
Multi-gene-parallel Analysis (NGS)
Single Gene Analysis (PCR, Microarrays)
By Biomarker:
Cell-free DNA (cfDNA)
Circulating Tumor DNA (ctDNA)
Extracellular Vesicles (EVs)
Circulating Tumor Cells (CTC)
Others
By Indication:
Small Cell Lung Cancer (SCLC)
Non-Small Cell Lung Cancer (NSCLC)
By Sample:
Blood
Cerebrospinal Fluid (CSF)
Plasma
Serum
Others
By End-user:
Hospitals
Reference Laboratories
Academic & Research Centers
Others
By Region:
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Lung Cancer Liquid Biopsy Snapshot, 2025-2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Product Adoption Analysis
3.2. Disease Epidemiology
3.3. Regulatory Landscape
3.4. List of Suppliers
3.5. Porter's Five Forces Analysis
3.6. PESTLE Analysis
3.7. Promotional Strategies, By Key Players
4. Global Lung Cancer Liquid Biopsy Outlook
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
4.3. Global Lung Cancer Liquid Biopsy Outlook: Product
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
4.3.3.1. Instruments
4.3.3.2. Kits and Reagents
4.3.3.3. Software and Services
4.3.4. Market Attractiveness Analysis: Product
4.4. Global Lung Cancer Liquid Biopsy Outlook: Technology
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Mn), By Technology, 2019-2024
4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
4.4.3.1. Multi-gene-parallel Analysis (NGS)
4.4.3.2. Single Gene Analysis (PCR Microarrays)
4.4.4. Market Attractiveness Analysis: Technology
4.5. Global Lung Cancer Liquid Biopsy Outlook: Biomarker
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn), By Biomarker, 2019-2024
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
4.5.3.1. Cell-free DNA (cfDNA)
4.5.3.2. Circulating tumor DNA (ctDNA)
4.5.3.3. Extracellular Vesicles (EVs)
4.5.3.4. Circulating Tumor Cells (CTC)
4.5.3.5. Others
4.5.4. Market Attractiveness Analysis: Biomarker
4.6. Global Lung Cancer Liquid Biopsy Outlook: Indication
4.6.1. Introduction / Key Findings
4.6.2. Historical Market Size (US$ Mn), By Indication, 2019-2024
4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
4.6.3.1. Small Cell Lung Cancer (SCLC)
4.6.3.2. Non-Small Cell Lung Cancer (NSCLC)
4.6.4. Market Attractiveness Analysis: Indication
4.7. Global Lung Cancer Liquid Biopsy Outlook: Sample
4.7.1. Introduction / Key Findings
4.7.2. Historical Market Size (US$ Mn), By Sample, 2019-2024
4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
4.7.3.1. Blood
4.7.3.2. Cerebrospinal Fluid (CSF)
4.7.3.3. Plasma
4.7.3.4. Serum
4.7.3.5. Others
4.7.4. Market Attractiveness Analysis: Sample
4.8. Global Lung Cancer Liquid Biopsy Outlook: End User
4.8.1. Introduction / Key Findings
4.8.2. Historical Market Size (US$ Mn), By End User, 2019-2024
4.8.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
4.8.3.1. Hospitals
4.8.3.2. Reference Laboratories
4.8.3.3. Academic & Research Institutes
4.8.3.4. Others
4.8.4. Market Attractiveness Analysis: End User
5. Global Lung Cancer Liquid Biopsy Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Lung Cancer Liquid Biopsy Outlook
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Product
6.2.3. By Technology
6.2.4. By Biomarker
6.2.5. By Indication
6.2.6. By Sample
6.2.7. By End User
6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
6.4.1. Instruments
6.4.2. Kits and Reagents
6.4.3. Software and Services
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
6.5.1. Multi-gene-parallel Analysis (NGS)
6.5.2. Single Gene Analysis (PCR Microarrays)
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
6.6.1. Cell-free DNA (cfDNA)
6.6.2. Circulating tumor DNA (ctDNA)
6.6.3. Extracellular Vesicles (EVs)
6.6.4. Circulating Tumor Cells (CTC)
6.6.5. Others
6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
6.7.1. Small Cell Lung Cancer (SCLC)
6.7.2. Non-Small Cell Lung Cancer (NSCLC)
6.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
6.8.1. Blood
6.8.2. Cerebrospinal Fluid (CSF)
6.8.3. Plasma
6.8.4. Serum
6.8.5. Others
6.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
6.9.1. Hospitals
6.9.2. Reference Laboratories
6.9.3. Academic & Research Institutes
6.9.4. Others
6.10. Market Attractiveness Analysis
7. Europe Lung Cancer Liquid Biopsy Outlook
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Product
7.2.3. By Technology
7.2.4. By Biomarker
7.2.5. By Indication
7.2.6. By Sample
7.2.7. By End User
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
7.4.1. Instruments
7.4.2. Kits and Reagents
7.4.3. Software and Services
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
7.5.1. Multi-gene-parallel Analysis (NGS)
7.5.2. Single Gene Analysis (PCR Microarrays)
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
7.6.1. Cell-free DNA (cfDNA)
7.6.2. Circulating tumor DNA (ctDNA)
7.6.3. Extracellular Vesicles (EVs)
7.6.4. Circulating Tumor Cells (CTC)
7.6.5. Others
7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
7.7.1. Small Cell Lung Cancer (SCLC)
7.7.2. Non-Small Cell Lung Cancer (NSCLC)
7.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
7.8.1. Blood
7.8.2. Cerebrospinal Fluid (CSF)
7.8.3. Plasma
7.8.4. Serum
7.8.5. Others
7.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
7.9.1. Hospitals
7.9.2. Reference Laboratories
7.9.3. Academic & Research Institutes
7.9.4. Others
7.10. Market Attractiveness Analysis
8. East Asia Lung Cancer Liquid Biopsy Outlook
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Product
8.2.3. By Technology
8.2.4. By Biomarker
8.2.5. By Indication
8.2.6. By Sample
8.2.7. By End User
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
8.4.1. Instruments
8.4.2. Kits and Reagents
8.4.3. Software and Services
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
8.5.1. Multi-gene-parallel Analysis (NGS)
8.5.2. Single Gene Analysis (PCR Microarrays)
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
8.6.1. Cell-free DNA (cfDNA)
8.6.2. Circulating tumor DNA (ctDNA)
8.6.3. Extracellular Vesicles (EVs)
8.6.4. Circulating Tumor Cells (CTC)
8.6.5. Others
8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
8.7.1. Small Cell Lung Cancer (SCLC)
8.7.2. Non-Small Cell Lung Cancer (NSCLC)
8.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
8.8.1. Blood
8.8.2. Cerebrospinal Fluid (CSF)
8.8.3. Plasma
8.8.4. Serum
8.8.5. Others
8.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
8.9.1. Hospitals
8.9.2. Reference Laboratories
8.9.3. Academic & Research Institutes
8.9.4. Others
8.10. Market Attractiveness Analysis
9. South Asia & Oceania Lung Cancer Liquid Biopsy Outlook
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Product
9.2.3. By Technology
9.2.4. By Biomarker
9.2.5. By Indication
9.2.6. By Sample
9.2.7. By End User
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
9.4.1. Instruments
9.4.2. Kits and Reagents
9.4.3. Software and Services
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
9.5.1. Multi-gene-parallel Analysis (NGS)
9.5.2. Single Gene Analysis (PCR Microarrays)
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
9.6.1. Cell-free DNA (cfDNA)
9.6.2. Circulating tumor DNA (ctDNA)
9.6.3. Extracellular Vesicles (EVs)
9.6.4. Circulating Tumor Cells (CTC)
9.6.5. Others
9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
9.7.1. Small Cell Lung Cancer (SCLC)
9.7.2. Non-Small Cell Lung Cancer (NSCLC)
9.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
9.8.1. Blood
9.8.2. Cerebrospinal Fluid (CSF)
9.8.3. Plasma
9.8.4. Serum
9.8.5. Others
9.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
9.9.1. Hospitals
9.9.2. Reference Laboratories
9.9.3. Academic & Research Institutes
9.9.4. Others
9.10. Market Attractiveness Analysis
10. Latin America Lung Cancer Liquid Biopsy Outlook
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Product
10.2.3. By Technology
10.2.4. By Biomarker
10.2.5. By Indication
10.2.6. By Sample
10.2.7. By End User
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
10.4.1. Instruments
10.4.2. Kits and Reagents
10.4.3. Software and Services
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
10.5.1. Multi-gene-parallel Analysis (NGS)
10.5.2. Single Gene Analysis (PCR Microarrays)
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
10.6.1. Cell-free DNA (cfDNA)
10.6.2. Circulating tumor DNA (ctDNA)
10.6.3. Extracellular Vesicles (EVs)
10.6.4. Circulating Tumor Cells (CTC)
10.6.5. Others
10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
10.7.1. Small Cell Lung Cancer (SCLC)
10.7.2. Non-Small Cell Lung Cancer (NSCLC)
10.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
10.8.1. Blood
10.8.2. Cerebrospinal Fluid (CSF)
10.8.3. Plasma
10.8.4. Serum
10.8.5. Others
10.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
10.9.1. Hospitals
10.9.2. Reference Laboratories
10.9.3. Academic & Research Institutes
10.9.4. Others
10.10. Market Attractiveness Analysis
11. Middle East & Africa Lung Cancer Liquid Biopsy Outlook
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Product
11.2.3. By Technology
11.2.4. By Biomarker
11.2.5. By Indication
11.2.6. By Sample
11.2.7. By End User
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
11.4.1. Instruments
11.4.2. Kits and Reagents
11.4.3. Software and Services
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
11.5.1. Multi-gene-parallel Analysis (NGS)
11.5.2. Single Gene Analysis (PCR Microarrays)
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
11.6.1. Cell-free DNA (cfDNA)
11.6.2. Circulating tumor DNA (ctDNA)
11.6.3. Extracellular Vesicles (EVs)
11.6.4. Circulating Tumor Cells (CTC)
11.6.5. Others
11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
11.7.1. Small Cell Lung Cancer (SCLC)
11.7.2. Non-Small Cell Lung Cancer (NSCLC)
11.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
11.8.1. Blood
11.8.2. Cerebrospinal Fluid (CSF)
11.8.3. Plasma
11.8.4. Serum
11.8.5. Others
11.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
11.9.1. Hospitals
11.9.2. Reference Laboratories
11.9.3. Academic & Research Institutes
11.9.4. Others
11.10. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Bio-Rad Laboratories, Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Agilent Technologies, Inc.
12.3.3. Oncocyte Corporation
12.3.4. NeoGenomics Laboratories
12.3.5. Lepu Medical Technology(Beijing)Co.,Ltd
12.3.6. QIAGEN
12.3.7. Thermo Fisher Scientific Inc.
12.3.8. Illumina, Inc.
12.3.9. F. Hoffmann-La Roche Ltd
12.3.10. Sysmex Corporation
12.3.11. BioView
12.3.12. Guardant Health, Inc
12.3.13. SOPHiA GENETICS
12.3.14. BioMark Diagnostics
12.3.15. DELFI Diagnostics, Inc.
12.3.16. Freenome Holdings, Inc.
12.3.17. Foresight Diagnostics, Inc.
12.3.18. Foundation Medicine, Inc.
12.3.19. Pillar Biosciences, Inc.
12.3.20. Caris Life Sciences
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations